Loading...

FundingHero

Stephen Johnson: Why Series A Funding is the Most Pivotal Phase

Introduction

For companies pursuing a VC-backed fundraising journey, the Series A investment is arguably the most pivotal phase for determining what scale the company can and will get to. For those seeking to pursue a big outcome, it’s the last chance you have to fundamentally “figure things out” and find (what appears to be) product/market fit. For Series B and beyond, investors want evidence you’ve found it.

But what does a Series A funding round really mean? It’s easy to look at outlier events over the past few years (see 1-year old Mistral AI raising a $113m seed in June 2023, $415m series A in December 2023, and a $640m series B in June 2024) and think these names don’t really count for much. But for the majority of the start-up and scale-up ecosystem, they still provide a helpful framework for determining where a company is in its journey and where it’s intending to go.

The world doesn’t need any more VC blog posts, but this one will hopefully be helpful in digging into what Series A is for the vast majority of companies; what investors tend to look for; how to prepare; what people get wrong; and what you should be aiming to achieve with the investment.

Understanding Series A Funding

The majority of venture capital funds are focused on particular stages in the fundraising journey (Seed, A, B etc.). This enables them to refine how they evaluate opportunities to make better investment decisions, as well as build an ecosystem of relationships (advisers, operating partners, follow-on VC funds) that help the companies they invest in to succeed. Funds who focus on specific sectors (e.g. software, Fintech, life sciences etc.) catalyse this even further.

Series A is usually the first significant round of venture capital financing, with the typical fundraise ranging from £3m-£15m, with the associated equity dilution of 10%-30%. It is also usually when investment comes from an institutional fund, rather than family and friends, angels, family offices etc. which are more common at Pre-Seed and Seed. The growth and direction of the company is typically still heavily reliant on the Founder(s) but there is now a real company established, with more fully formed people infrastructure in both developing the product/service and in go-to-market/distribution. It isn’t entirely predictable or repeatable yet, but there is evidence of success outside of relying on the Founder(s) black book/past relationships for winning customers.

Am I a Series A ready company?

In our experience, companies that succeed in raising a Series A share some the following traits:

  • The CEO has clarity on the long-term vision, strategy, execution plans and associated value milestones for the company.
  • They are in the early stages of assembling an executive team capable of delivering on these milestones.
  • The company has a refined product or service offering that is usable by their target customers, and offers substantial benefit over existing solutions.
  • They have an ideal customer profile (ICP); know how customers derive value from the product; and how value will be captured through pricing.
  • There is a large enough market opportunity for the value proposition to build a substantial business (we’ll come back to this point below). This is evidenced by bottom-up market sizing analysis based on realistic pricing assumptions and analysis of the number of prospective customers (see definitions of TAM, SAM and SOM).
  • There is building evidence of market traction – either customers using or paying for the product or service. Real revenue is the best form of this but it will depend based on the sector.
  • There is early evidence of the company being able to acquire, onboard and retain customers, whilst doing so profitably on a profitable unit economic basis. This means the economics of the business model at scale make sense.

Where this really differs to earlier and later stage funding rounds:

  • Seed – requires less market validation and the company is usually earlier in developing and refining the product or service offering. Fundamentally this stage is all about backing a Founder (or Founders) working on building a compelling solution to a big problem.
  • Series B – needs more evidence of market traction/revenue and have proven capable of growing quickly whilst demonstrating strong unit economics. There’s evidence of an expansive market opportunity, and ideally scope to build out further products and services. Getting to this point is often the target objective of series A funding.

How should I prepare for Series A?

Approach conversations with investors as you would conversations with your customers – seek to solve their problems for them. Almost all VC’s primary “problem” is to generate outsized returns for their investors based on the agreed investment strategy (their “investment mandate”). Therefore your focus should be on explaining how your company can help them do that. Have 100% clarity of where you are going to take the company, and how why it will be valuable when you get there. The less that is built on hope value, the better. Good investors should reciprocate in treating you like a customer too: seeking to help you solve your problems too, both pre and post-investment.

Be aware that investors will evaluate your company through two lenses – the business case and the investment case:

Business Case Investment Case
·      Team capability

·      Product differentiation

·      Market size

·      Competitive landscape

·      Unit economics/financials

·      Investment “entry” valuation

·      Company’s future funding needs

·      # of follow-on funds with likely interest

·      Likely “exit” valuation/investment returns

·      Volume and appetite of likely acquirers

Company valuation is far too big a topic for a blog post, but all investors will look at the fully-diluted post-money valuation on this front (pre-money valuation + investment amount) to reverse engineer their anticipated returns based on a series of potential outcomes. They will also factor in future funding rounds, including any further participation they might make and any equity dilution they might incur. These return scenarios will range from achieving the “shoot for the moon” goal to total failure, but across all scenarios the risk adjusted return needs to make sense for them.

What do Founders tend to get wrong when raising a series A investment?

Below are some of the more common things we see founders “get wrong” – where funds don’t invest and the Founder could have done something to prevent it:

  • Lack of clarity over future value milestones beyond just an ambitious financial forecast. Series A requires a good handle on how you will deliver the growth plan, based on thorough unit economic and financial calculations of what funding inputs will generate what revenue outputs (or alternative milestones to revenue e.g. FDA approval and reimbursement in pharma and medical devices, technology readiness level (TRL) in manufacturing). This includes the business model being economically viable. A common example would be using a sales-led motion to sell a low cost software product. If a sales rep can’t deliver 4-5x their on-target earnings in new bookings, the business model is very unlikely to work. Be clear on your base case plan and then have some upside “moonshot” initiatives.
  • Comparing the UK venture capital market with the US equivalent. The US has a population of c. 5x the UK which alone presents a bigger market opportunity for companies. B2B customers are generally more willing to adopt new products, particularly within software, and are willing to spend more in the process. In general, salaries (as at the time of writing) are also much higher. The US also benefits from the world’s deepest and most mature venture capital ecosystem, which benefits founders and VCs themselves (particularly with follow-on funding rounds). These variables all lead to pros and cons for UK vs. US founders, but what is for sure is they are not the same markets.
  • The investment case doesn’t make sense, usually based on the expected entry valuation relative to the risk adjusted outcome. Founders hear of other companies achieving high valuation multiples in a fundraise and assume their company can achieve the same, however every company and funding round is unique. Fundamentally the prize you’re going after needs to be big enough (through refined analysis of what your true serviceable obtainable market is), and the investor needs to believe you can capture it. The more evidence you have of your ability to get there quickly – existing revenue scale and current growth rate – the more attractive the business will appear and the higher the price. If you’re planning to raise further funding, the Series A valuation shouldn’t be prohibitively high that a Series B investor can’t make at least a 5-10x return on their investment. It can help to think a few steps ahead rather than maximising in the here and now. Fundamentally as with anything, companies are always worth what someone is willing to pay.

What are the typical objectives of a series-A round?

To grow the company to something that is worth more! The future ambitions of the company will determine what this means in detail. Many will seek to aggressively raise further funding rounds (series B, C+ etc.) if the ambition is to build a company of major scale. Others may prefer optionality and will instead seek to reach breakeven, perhaps accepting a lower growth rate, but only raise further growth capital if they so wish. To illustrate, below are two hypothetical scenarios from a series A round:

  • Efficiency Software Inc. – raised a £6m series A round, was at £2.5m annual recurring revenue (ARR) having grown 100% year-on-year (YoY) at the time of investment, burning £200k/month in losses. Achieved £6m ARR 2 years later and was still growing revenue at 50% YoY, and was cash flow break even.
  • To the Moon Software Ltd. – raised a £15m series A round, was at £2.5m ARR having grown 500% YoY at the time of investment, burning £350k/month in losses. Achieved £8m ARR 12 months later and was still growing revenue at 300% YoY, but was still burning £700k/month in losses.

Company B will almost certainly be worth substantially more than company A at this point due to the exceptional growth rate (VC is all about growth), but there is still a lot more risk to the Founders and existing investors given the company has no choice but to raise more funding to keep the dream alive. Any investor coming in at that point will expect to make a substantial return on their money, which sets expectations about what the company needs to achieve going forwards. Company A is still growing and should continue to grow into a valuable business, and benefits from optionality over whether or not they raise further funding. But it is much more unlikely that this company will grow into a truly substantial business in the near term.

Neither approach is right or wrong. Different funds have different appetites towards these types of investments – one is higher risk/higher reward than the other. What is most important is finding an investor that aligns with what you as the Founder (and the rest of your shareholders, board, team) want to do. Again this topic deserves it’s own blog to help Founders figure this out.

Wrap-up

Raising a series A should be the transformative step that enables a start-up to become a scale-up. There are a lot of variables at play, but the most important point to take away is go into the process with a full understanding of your business, vision, strategy and plans; and during the process seek to find an investor who is fully aligned with investing in that and can help along the way. It will no doubt take more time and energy than you expect, but when you find an investor you click with and have the capital in the bank to invest, it will be worth it.

Stephen Johnson is a seasoned investment professional with extensive experience in venture capital and private equity. Currently at Mercia Asset Management PLC, he specializes in supporting early-stage and scale-up businesses across the UK. Stephen is passionate about helping founders navigate the complexities of fundraising and growth strategy. He holds a degree from Loughborough University and is known for his hands-on approach to guiding startups through the investment landscape.

Person reading blog
Request Form

Book a Demo

Kindly fill in the application form and we will get back to you once we review your application

Jack Molyneux

Traditional Shipwright and Master Mariner, Superyacht expert.

Passionate about changing the industry for the better. Our mission is to create the world’s first digital marketplace for superyacht ownership, charter and investment.

Dr. Sivaram Nishal Ramadas

Celmetrix offers a cutting-edge rapid battery tester that uses advanced sensors and edge analytics to provide real-time, multi-point inspection, ensuring every cell meets the highest quality standards. By detecting defects early in production, it reduces waste, cuts costs, and empowers manufacturers to produce safer, more reliable batteries efficiently.

Debra Glover

Iron & Velvet is a company that makes plastic-free cleaning products. Their products are water-soluble sachets that dissolve in water, making them kind to the environment. The company also sells a variety of other sustainable products, such as vegan and cruelty-free cleaning products. Iron & Velvet is committed to providing customers with high-quality, sustainable cleaning products that are good for the environment and good for the home.

Dr Henry James, Dr Matthew Tranter & Dr Volodymyr Chapman

Medscribe eliminates the burden of medical admin and gives clinicians their time back, saving the NHS millions in the process. By automating clinical documentation, Medscribe slashes hours of paperwork, freeing up healthcare professionals to focus on what matters most: patient care. Built by doctors for doctors, with unique safety features, we’re unlocking new levels of efficiency, accuracy, and job satisfaction across the healthcare system.

Eugene Patterson

Elevate Your Everyday with Revibed Drinks- superfood-infused beverages designed to fuel your body with essential nutrients while delivering great taste. Stocked in major retailers like Holland & Barrett, Co-op and Ocado. We’re making functional wellness more accessible, helping you stay energised, healthy and refreshed every day.

Francesca & Dominic Fox

Francesca and Dominic, co-founders, embody yin and yang management. Francesca has 10 years in healthcare commercialisation, while Dominic brings 20 years in professional sport and 10 years in marketing.

Imagine a world where revolutionary, personalised stem cell therapy is accessible to everyone at a cost lower than an NHS prescription. Our cutting-edge technology is making this vision a reality, providing life-changing non-pharmaceutical treatments, ensuring that advanced healthcare is within reach for all.

Umar Butt

With a vision of a world where learning to drive is accessible, straightforward, and free from unnecessary complications. The mission of ErmoL is to revolutionise the driving instruction industry through transparency, efficiency, and putting learners first.

Scott Garrett

VitaVoice is the UK’s first preventative vocal health supplement, trusted by West End stars and major soap actors. Formulated to prevent voice issues, not just mask them with cough sweets, it boosts vocal health, cognition, and performance. With over 5 million professional voice users in the UK, VitaVoice is capturing a massive, underserved market.

Henry Clark

TDI Greenway is a market leader in the design, manufacture and deployment of Very Light Rail (VLR)vehicles and lightweight mass transit solutions that are up to 80% cheaper than heavy rail alternatives and 3x quicker to deploy. VLR technology allows for battery-only propulsion systems and net-zero operation to support government decarbonisation targets, offering greener mass transport options the worlds communities.

Dr Matthew Bacon

TCC-CASEMIX, a health informatics platform, revolutionises healthcare by addressing critical inefficiencies in data capture and analysis during surgeries. Through partnerships with NHS Trusts, and a current client base that includes major Medical Device Manufacturers, the company has been validated in clinical environments and is now rapidly scaling.

Tim Telford

UK manufacturing is under siege. From the birthplace of the Industrial Revolution, Devtank is disrupting the industry with our award-winning production test and smart monitoring solutions. We play a critical part of the manufacturing data revolution. As industry leading veterans, our solutions drive productivity, energy reduction, quality and environmental improvements.

Paul Rivers

UK manufacturing needs to become more competitive, profitable and efficient. AI and Automation can contribute. We have automation solutions and software that we provide to UK businesses to bring about productivity increases. Automation is usually a large CapEx, but we lend the solution that’s right for a clients business which gives then the quickest gain. For every hour of human labour that is saved with our solution, we charge half of the human “living wage” per hour, charged monthly. We effectively share the savings, instant ROI, no risk to customer, but all of the benefits.

Dr Mahdi Mohammad-pour

TriboDENS is a company that uses software and experimental techniques to address engineering challenges in tribology, dynamics, and energy solutions. The company offers solutions for noise, vibration, and harshness (NVH) and tribology of mechanical systems. TriboDENS’s mission is to help companies improve the performance and efficiency of their mechanical systems.

Adriano Randi

R3V Tech is a spinout company from Loughborough University that focuses on creating new revenue streams for industry via circular economy approaches. Their main product is ‘Solketal’, a high-value, eco-friendly bio-derived chemical with diverse industrial through innovative process technology. They offer a cost-effective approach based at the process plants of individual biodiesel producers, using mild conditions at lower break-even volumes than traditional production methods.

Dan Lane

ValidateLabs presents a ground breaking B2B SAAS product for clinical laboratories. It’s AI technology automates the test validation process, reducing the time to complete validation from 3 weeks to 3 minutes!

The platform is currently in beta trials in over 10 clinical lab environments and saving labs huge amounts of time, money, and valuable resource to increase labs outputs and bringing more invaluable clinical tests to use rapidly quicker.

Neuro-Notion

Josh Budd

The world’s first life management and education platform scientifically designed for Adults with ADHD. After growing up and being expelled from school 15 times, due to Josh’s undiagnosed severe ADHD, he’s now building a platform which is desperately needed with the rapid rise of ADHD diagnoses and allows Adults with ADHD to regain control of their lives through positive habits, routines, mental health and everything else in between.a

Accelerator Programme

Registration Form

Applications are currently closed. Please check back later when a new cohort is available!

Kindly fill in the application form and we will get back to you once we review your application